Healthcare entity
All 1 tracked stories fall under one category: market-trends. Amtagvi is most often covered alongside FDA, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Amtagvi, all published on February 23, 2026.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Amtagvi is most often covered alongside FDA, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Amtagvi, all published on February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amtagvi. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Preview
Analysts project significant revenue growth from Amtagvi sales.
Commercial Expansion
Iovance scales ATC network to over 50 centers nationwide.
FDA Approval
Amtagvi receives accelerated approval for metastatic melanoma.
Iovance Biotherapeutics is set to report Q4 2025 results, with investors laser-focused on the commercial trajectory of Amtagvi, the first FDA-approved TIL therapy. The report will provide critical data on treatment center onboarding, patient enrollment, and the company's path toward profitability in the cell therapy space.
Source: Seeking Alpha · Seeking Alpha
Amtagvi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
